Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide in Autism Medication and Biomarker Study
2014-001560-35Phase 2Active
- Sponsor
- UMC Utrecht Brain Center
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of bumetanide in Autism Spectrum Disorder (ASD), sponsored by UMC Utrecht Brain Center. Primary endpoint: Social Responsiveness Scale (SRS). Started Jan 2016; status: active.
02
Drugs
bumetanide
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2014-001560-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001560-35.